
Feature|Articles|May 5, 2026
Psychedelic Therapy EO Is a Major Step for Mental Health, but Access Barriers Remain, Experts Say
Author(s)Giuliana Grossi
Fact checked by: Christina Mattina
New executive order fast-tracks psychedelic therapy research for veterans, but VA rollout, DEA rescheduling, and insurance hurdles still loom.
Advertisement
Advertisement
For decades, psychedelic medicine has occupied a complex and often contentious space between restrictive federal scheduling and emerging clinical research. However, a recent
Related to this article

At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.

CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.

At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.

As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.

Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.

Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
Advertisement
Advertisement

